おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
HiFiBiO
About
HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
- 101 - 250
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $75M
- Industries
- Biopharma,Biotechnology,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2013
- Number Of Employee
- 101 - 250
- Operating Status
- Active
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 14, 2021 | Series D | $75M | 2 | — | — | Detail |
| Aug 28, 2019 | Series C | $67M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Hong Kong Science and Technology Parks Corporation (HKSTP)
|
— | Series D |
|
|
— | Series D |
Kite Pharma
|
— | Series C |
VI Ventures
|
— | Series C |
